Wells Fargo & Company Leap Therapeutics, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.29 - $0.72 $33 - $82	115 Added 21.86%	641 $0
Q4 2022 Feb 13, 2023	BUY	$0.42 - $9.18 $5 - $119	13 Added 2.53%	526 $0
Q3 2022 Nov 14, 2022	BUY	$0.92 - $9.3 $85 - $864	93 Added 22.14%	513 $0
Q2 2022 Aug 12, 2022	BUY	$0.96 - $1.91 $403 - $802	420 New	420 $0
Q4 2021 Feb 14, 2022	SELL	$2.08 - $3.65 $10,840 - $19,023	-5,212 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$1.35 - $4.01 $772 - $2,293	-572 Reduced 9.89%	5,212 $21,000
Q2 2021 Aug 16, 2021	SELL	$1.48 - $1.92 $2 - $3	-2 Reduced 0.03%	5,784 $9,000
Q1 2021 May 13, 2021	SELL	$1.82 - $3.01 $74,832 - $123,762	-41,117 Reduced 87.66%	5,786 $12,000
Q4 2020 Feb 09, 2021	BUY	$1.49 - $2.37 $65,007 - $103,400	43,629 Added 1332.59%	46,903 $106,000
Q3 2020 Nov 05, 2020	BUY	$1.68 - $2.17 $5,347 - $6,907	3,183 Added 3497.8%	3,274 $7,000
Q1 2020 May 14, 2020	BUY	$1.06 - $2.94 $96 - $267	91 New	91 $0

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $275M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.